Clinical Trial Update: Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias [Phase 3]

View source ↗

Summary

Phase 3 trial investigating octreotide for reducing blood and iron requirements in anemia due to angiodysplasias; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Angiodysplasia
• Gastrointestinal Hemorrhage
• Vascular Malformations

Drugs mentioned

• OCTREOTIDE (OCTREOTIDE ACETATE)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Angiodysplasia, Vascular Malformations | Phase 3 | Status: COMPLETED